AHCO
AdaptHealth Corp.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
5.53
▲ 0.14 (2.60%)
MARKET · —
Price
Open
5.39
Prev close
5.39
Day high
5.64
Day low
5.36
Volume
1.92M
Market cap
$751.09M
P/E (TTM)
—
52W range
5.21 – 13.43
Trailing performance
Returnvs SPY
1W
-3.10%
-1.7%
1M
-46.23%
-50.0%
3M
-46.53%
-49.6%
6M
-45.55%
-56.6%
YTD
-43.47%
-55.8%
1Y
-39.66%
-59.7%
3Y
-58.20%
-132.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$751.09M
Enterprise value$2.78B
Revenue (TTM)$3.36B
Gross profit$644.93M
EBITDA$583.47M
Net income$-231.10M
EPS (TTM)$-1.71
Free cash flow$-80.69M
Total cash$43.29M
Total debt$2.07B
Book value / share$10.34
Shares outstanding133.41M
Float85.77M
Short % of float8.05%
Dividend yield—
Beta (5Y)1.46
Valuation & profitability ratios
Trailing P/E—
Forward P/E-43.98
PEG ratio—
Price / sales—
Price / book0.54
EV / revenue0.83
EV / EBITDA4.77
Gross margin19.17%
Operating margin0.84%
Profit margin-6.79%
Return on equity-15.22%
Return on assets2.28%
Debt / equity148.97
Current ratio1.12
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $3.24B | $3.26B | $3.20B | $2.97B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$70.79M | $90.42M | -$678.89M | $69.32M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$70.79M | $90.42M | -$678.89M | $69.32M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.17 | -0.07 | -139.5% |
| Mar 2026 | 0.01 | -0.05 | -529.7% |
| Dec 2025 | 0.34 | 0.27 | -20.8% |
| Sep 2025 | 0.24 | 0.23 | -2.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.06 | 5 | $725.98M | -11.5% |
| Next quarter | -0.06 | 5 | $736.51M | -13.0% |
| Current year | -0.45 | 5 | $2.88B | -11.3% |
| Next year | -0.13 | 5 | $2.99B | +3.9% |
Analyst targets & ownership
Mean target$9.14
High target$10.00
Low target$7.00
Implied upside65.33%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders8.14%
Held by institutions108.71%
Institutions holding342
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+5.49M
Net buying
Buy transactions
21
5.52M shares
Sell transactions
2
22.55K shares
Net transactions
+23
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
10.86M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 7, 26 | WOLF DALE B Director |
BUY | 40.00K | $244.60K | |
| Aug 6, 26 | WOLF DALE B Director |
BUY | 20.00K | $126.00K | Direct |
| Aug 6, 26 | SAMET KENNETH A Director |
BUY | 23.50K | $149.93K | Direct |
| Jul 1, 26 | SCHUSTER RUSSELL E. III Officer |
SELL | 11.28K | $117.71K | Direct |
| Jun 24, 26 | WOLF DALE B Director |
STOCK | 19.00K | $0 | Direct |
| Jun 24, 26 | SAMET KENNETH A Director |
STOCK | 25.07K | $60.03K | Direct |
| Jun 24, 26 | BELINFANTI GREGORY A Director |
STOCK | 19.00K | $0 | Direct |
| Jun 24, 26 | COPPENS BRADLEY J Director |
STOCK | 19.00K | $0 | Direct |
| Jun 24, 26 | WEAVER SUSAN T. Director |
STOCK | 19.00K | $0 | Direct |
| Jun 24, 26 | CONNORS TERENCE J. Director |
STOCK | 19.00K | $0 | Direct |
| Jun 24, 26 | WILLIAMS DAVID SOLOMON III Director |
STOCK | 19.00K | $0 | Direct |
| Jun 24, 26 | LUNDBERG THEODORE B. Director |
STOCK | 19.00K | $0 | Direct |
| Jun 1, 26 | SCHUSTER RUSSELL E. III Officer |
SELL | 11.28K | $113.43K | Direct |
| May 27, 26 | MCFADDEN DANIEL EDWARD Chief Operating Officer |
STOCK | 20.13K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARNHART TOBY SCOTT |
Chief Operating Officer | 220.65K | Stock Award(Grant) |
CASHIN RICHARD M JR |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
CLEMENS JASON A |
Chief Financial Officer | 673.48K | Stock Award(Grant) |
FOSTER SUZANNE |
Chief Executive Officer | 924.05K | Stock Award(Grant) |
LUNDBERG THEODORE B. |
Director | 892.50K | Stock Award(Grant) |
OEP VII GP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
PRAST ALBERT A. |
Chief Technology Officer | 474.15K | Conversion of Exercise of derivative security |
RIETKERK SHAW |
Chief Operating Officer | 212.61K | Sale |
SCHUSTER RUSSELL E. III |
Officer | 125.26K | Sale |
WOLF DALE B |
Director | — | Purchase |
Moving averages & technicals
SMA 10
5.65
-2.05% from price
SMA 20
7.33
-23.23% from price
SMA 50
9.12
-38.26% from price
SMA 100
10.30
-46.32% from price
SMA 200
10.17
-44.64% from price
EMA 12
6.19
-10.65% from price
EMA 26
7.42
-25.44% from price
EMA 50
8.54
-35.24% from price
RSI (14)
26.9
Oversold
MACD (12,26,9)
-1.23
Hist -0.06
ATR (14)
0.69
12.17% of price
Realised vol 30D
146.5%
Annualised
Bollinger upper
12.02
20, 2σ
Bollinger lower
2.65
20, 2σ
50 / 200 cross
Death
9.12 vs 10.17
Trend bias
Below 200
-44.64%
Risk profile
Beta vs SPY
-0.01
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
146.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-61.0%
Peak to trough
Max drawdown 5Y
-80.8%
Peak to trough
ATR 14
0.69
12.17% of price
Beta (reported)
1.46
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
1.21
Positioning, not flow
Max pain
15.00
+166.4% from spot
ATM implied vol
64.8%
Nearest strike to spot
Skew (10% OTM)
-10.2%
Calls bid over puts
Call volume
149
Contracts, this expiry
Put volume
26
Contracts, this expiry
Heaviest call OI
10.00
3.57K contracts
Heaviest put OI
15.00
4.97K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health
PR Newswire · 5d ago
1 Cash-Producing Stock to Consider Right Now and 2 Facing Challenges
StockStory · 6d ago
3 of Wall Street’s Favorite Stocks That Fall Short
StockStory · 7d ago
5 Must-Read Analyst Questions From AdaptHealth’s Q2 Earnings Call
StockStory · 10d ago
AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Why Cardinal Health Stock Is Heading for a Record After Mixed Earnings
Barrons.com · 11d ago
AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth
MarketBeat · 11d ago
Why AdaptHealth Stock Plummeted This Week
Motley Fool · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.